BPC-157 vs TB-500: What's the Difference

BPC-157 and TB-500 are two distinct research peptides, different in origin, structure and mechanism of action. They show up together across a lot of the literature because both are studied in tissue-repair models, but that doesn't make them equivalent or interchangeable: each acts through a separate pathway, and the papers that describe them treat them as separate compounds, not synonyms.

What BPC-157 is

BPC-157 (Body Protection Compound-157) is a synthetic peptide derived from a partial sequence of a gastric protein. It's stable in acidic conditions, which is why a large share of the early research concentrated on digestive models. Later literature broadened to connective tissue, blood vessels and wound-healing models, where researchers investigate its interaction with pathways related to growth factor receptors and nitric oxide signaling.

It's one of the compounds in PeptoClinic's catalog, supplied as lyophilized material for laboratory research. For researchers sourcing into Argentina, PeptoClinic keeps a dedicated page on BPC-157 in Argentina with the documentation and import logistics detail.

What TB-500 is

TB-500 is the synthetic version of an active fragment of thymosin beta-4 (Tβ4), a small protein present in nearly all mammalian cells. Thymosin beta-4 binds to G-actin, one of the cell's structural components, and through that pathway the literature links it to cell migration and angiogenesis in animal models. TB-500 retains the portion of the molecule responsible for that actin binding, which is exactly what's being investigated in wound-healing and vascular remodeling studies.

Unlike BPC-157, TB-500 isn't a gastric derivative and doesn't share the same sequence family: these are molecules of distinct biological origin that arrived at similar research areas by separate routes.

Where the mechanisms actually diverge

The central difference between the two is the molecular target:

• BPC-157 is studied in relation to growth factor receptors and the nitric oxide pathway, and its stability in acidic conditions made it an early candidate of interest for gastrointestinal research before extending to other tissues.
• TB-500 is studied for its direct binding to G-actin, which in cellular models translates into effects on cell motility and new blood vessel formation.

These are non-overlapping mechanisms. That the literature frequently mentions them in the same paragraph reflects that the study models (tendon, ligament, skin, cardiac tissue) are shared, not that the compound is the same or acts the same way.

Why they show up together in the literature

Several animal-model research papers evaluate BPC-157 and TB-500 within the same experimental protocol, often in combination, because researchers want to compare or stack two distinct pathways within the same tissue-injury model. That's why laboratory preparations exist that combine both peptides in a single vial, built for experimental protocols that need to administer both compounds together without reconstituting them separately.

PeptoClinic has laboratory documentation for a combined BPC-157 and TB-500 preparation, with declared content detailed in the corresponding certificate of analysis. Outside of that specific combination, each peptide is also quoted individually.

What the certificate of analysis (COA) says

PeptoClinic doesn't publish a purity claim without a laboratory report behind it. Batches are analyzed by Janoshik Analytical, an independent third-party laboratory, and every report is available for a buyer to review before deciding. The quality and certificates of analysis page has the full detail: which compound was tested, on what date, and what content was found against the label claim. Janoshik's own site is at janoshik.com.

That's what separates a verifiable supplier from one that just writes "guaranteed purity" with nothing behind it: the number has to resolve to a document signed by a laboratory, not a line on a product page.

Research use only (RUO)

BPC-157 and TB-500, like PeptoClinic's entire catalog, are supplied strictly for Research Use Only (RUO): in vitro and laboratory studies. Neither is a medicine, a supplement, or a product approved for human or veterinary consumption, diagnosis, or treatment. No claim about these compounds has been evaluated by the FDA, ANMAT, or any equivalent regulatory authority. Reference for peptide classification and oversight is available from the FDA. PeptoClinic is not a pharmacy, a clinic, or a telehealth provider, and does not offer dosing, administration, or protocol guidance for use in people — that kind of request is declined.

Documentation and shipping to Argentina

Orders quoted to Argentine destinations are prepared with the corresponding customs documentation for entry as laboratory reference material. The material travels lyophilized, in a sealed vial with desiccant and protected from light, at room temperature: it doesn't require a cold chain, because lyophilized powder is stable under those conditions for weeks. Full detail on packaging and the destinations served is on the shipping page.